Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Share-based Compensation (2018 - 2025)

X4 Pharmaceuticals' Share-based Compensation history spans 8 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 2.44% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $4.3 million, down 47.61%, while the annual FY2025 figure was $4.3 million, 47.61% down from the prior year.
  • Share-based Compensation reached $2.3 million in Q4 2025 per XFOR's latest filing, up from $760000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.5 million in Q4 2023 to a low of $519000.0 in Q1 2025.
  • Average Share-based Compensation over 5 years is $1.6 million, with a median of $1.6 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: surged 129.36% in 2023, then plummeted 70.16% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $1.6 million in 2021, then plummeted by 31.2% to $1.1 million in 2022, then soared by 129.36% to $2.5 million in 2023, then fell by 12.68% to $2.2 million in 2024, then grew by 2.44% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Share-based Compensation are $2.3 million (Q4 2025), $760000.0 (Q3 2025), and $748000.0 (Q2 2025).